These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6106954)

  • 21. Smooth pursuit eye movements in schizophrenia: influences of neuroleptic treatment and the question of specificity.
    Küfferle B; Friedmann A; Topitz A; Földes P; Anderer P; Kutzer M; Steinberger K
    Psychopathology; 1990; 23(2):106-14. PubMed ID: 1979684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response of postpsychotic depression to adjunctive imipramine or amitriptyline.
    Siris SG; Rifkin AE; Reardon GT
    J Clin Psychiatry; 1982 Dec; 43(12):485-6. PubMed ID: 6131064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidepressant usage in schizophrenia.
    Plasky P
    Schizophr Bull; 1991; 17(4):649-57. PubMed ID: 1687176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depressive syndromes in schizophrenic patients under neuroleptic therapy. ANI Study Group Berlin, Düsseldorf, Göttingen, Munich, Federal Republic of Germany.
    Bandelow B; Müller P; Frick U; Gaebel W; Linden M; Müller-Spahn F; Pietzcker A; Tegeler J
    Eur Arch Psychiatry Clin Neurosci; 1992; 241(5):291-5. PubMed ID: 1351405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Akinesia and postpsychotic depression: a difficult differential diagnosis.
    Siris SG
    J Clin Psychiatry; 1987 Jun; 48(6):240-3. PubMed ID: 2884213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Action and tolerance of dothiepin hydrochloride (Prothiaden) in depressive states during the evolution of psychotic disorders].
    Sechter D; De Sahb R; Boudet A; Leutenegger E
    Encephale; 1994; 20(4):445-50. PubMed ID: 7988409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyproheptadine in treatment-resistant chronic schizophrenics with prior negative response to fluoxetine.
    Bacher NM; Sanzone MM; Kaup B
    J Clin Psychopharmacol; 1994 Dec; 14(6):424-5. PubMed ID: 7884024
    [No Abstract]   [Full Text] [Related]  

  • 28. [Depressive syndromes within the scope of schizophrenic diseases].
    Heim M
    Psychiatr Neurol Med Psychol (Leipz); 1986 Dec; 38(12):716-21. PubMed ID: 3575544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding depression in schizophrenia.
    Weiss KJ; Valdiserri EV; Dubin WR
    Hosp Community Psychiatry; 1989 Aug; 40(8):849-51. PubMed ID: 2569438
    [No Abstract]   [Full Text] [Related]  

  • 30. [Primary, non-pharmacogenic depressions in schizophrenia].
    Huszár I
    Psychiatr Neurol Med Psychol Beih; 1988; 41():40-2. PubMed ID: 2908254
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical characteristics, health beliefs and compliance with maintenance treatment: a comparison between regular and irregular attenders at a depot clinic.
    Pan PC; Tantam D
    Acta Psychiatr Scand; 1989 Jun; 79(6):564-70. PubMed ID: 2569803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treating depression in schizophrenic patients.
    Seeman MV; McGee H
    Am J Psychother; 1982 Jan; 36(1):14-22. PubMed ID: 6123265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant psychotropic medication use during treatment of schizophrenia patients: longitudinal results from the CATIE study.
    Chakos M; Patel JK; Rosenheck R; Glick ID; Hammer MB; Tapp A; Miller A; Miller D
    Clin Schizophr Relat Psychoses; 2011 Oct; 5(3):124-34. PubMed ID: 21983496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Depressive symptoms and schizophrenia a psychopharmacological approach.
    Mauri MC; Bravin S; Fabiano L; Vanni S; Boscati L; Invernizzi G
    Encephale; 1995; 21(5):555-8. PubMed ID: 8529564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of creatine kinase in the diagnosis of neuroleptic malignant syndrome.
    O'Dwyer AM; Sheppard NP
    Psychol Med; 1993 May; 23(2):323-6. PubMed ID: 8101383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment.
    Peralta V; Cuesta MJ; Martinez-Larrea A; Serrano JF
    Am J Psychiatry; 2000 Sep; 157(9):1461-6. PubMed ID: 10964863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychotogenic drug use and neuroleptic response.
    Bowers MB; Mazure CM; Nelson JC; Jatlow PI
    Schizophr Bull; 1990; 16(1):81-5. PubMed ID: 1970670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The appropriateness of routine medication treatment for schizophrenia.
    Young AS; Niv N; Cohen AN; Kessler C; McNagny K
    Schizophr Bull; 2010 Jul; 36(4):732-9. PubMed ID: 18997159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noncompliance with antiparkinsonian medications in neuroleptic-treated schizophrenic patients: three cases of an unreported phenomenon.
    Bermanzohn PC; Siris SG
    J Clin Psychiatry; 1994 Nov; 55(11):488-91. PubMed ID: 7989282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes.
    Krakowski M; Czobor P; Volavka J
    Psychiatry Res; 1997 Jun; 71(1):19-26. PubMed ID: 9247978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.